Actively Recruiting
Breast Cancer PSMA PET
Led by Ahmad Shariftabrizi · Updated on 2026-03-27
30
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
Sponsors
A
Ahmad Shariftabrizi
Lead Sponsor
P
Progenics Pharmaceuticals, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
CONDITIONS
Official Title
Breast Cancer PSMA PET
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female 18 years of age or older
- Diagnosed with metastatic Triple Negative Breast Cancer based on initial biopsy
- Presence of FDG positive metastatic lesions on the initial PET/CT scan performed in this study
You will not qualify if you...
- Having any other active malignancy
- Unable to tolerate the PET/CT procedure
- Pregnant or breastfeeding
- Having any medical condition that could compromise safety during PET imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Iowa Healthcare
Iowa City, Iowa, United States, 52242
Actively Recruiting
Research Team
A
Ahmad Shariftabrizi, M.D.
CONTACT
E
Elina Shrestha
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here